Sonoma Pharmaceuticals (NASDAQ: SNOA) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.31) by 54.84 percent. This is a 23.81 percent increase over losses of $(0.63) per share from the same period last year. The company reported quarterly sales of $4.349 million which beat the analyst consensus estimate of $4.326 million by 0.53 percent. This is a 22.03 percent increase over sales of $3.564 million the same period last year.